… However, with the introduction of high-dose melphalan (HDM) and supporting
autologous stem-cell transplantation (ASCT), it became evident that the achievement of …

Poulter and colleagues describe a series from the United Kingdom of 10 male patients with
VEXAS syndrome, including 2 with novel genetic changes affecting methionine 41 of E1.

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10 −4
) after treatment is an independent predictor of progression-free survival (PFS), but not …

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies
- de Tute - 2011 - Histopathology - Wiley Online Library … Ruth M de Tute … Ruth M de Tute …

PURPOSE Minimal residual disease (MRD) can predict outcomes in patients with multiple
myeloma, but limited data are available on the prognostic impact of MRD when assessed at …

PURPOSE The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab,
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …

People with myeloma who obtain a good response to treatment have a better survival if
sensitive molecular or flow‐cytometric techniques show no detectable minimal residual disease (…

The purpose of this study was to use multiparameter flow cytometry to detect occult marrow
disease (OMD) in patients with solitary plasmacytoma of bone and assess its value in …

… Ruth M de Tute, PhD Ruth M de Tute … The ATLAS study is currently investigating KRd
maintenance after autologous HSCT, with de-escalation to lenalidomide for MRD-negative patients …

Introduction Lenalidomide maintenance after autologous stem cell transplant (ASCT) is
standard of care for myeloma (MM) patients, based on trials in which lenalidomide was planned …